Camptothecin ADC Payload Composition for Plasma Stability and Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current camptothecin derivatives used in antibody-drug conjugates (ADCs) for anti-tumor treatment lack sufficient therapeutic efficacy and safety, necessitating the development of improved compounds with enhanced inhibitory activity against tumor cells, targeting capability, plasma stability, bystander effect, and in vivo tumor inhibition.
Innovation Solution
Development of compounds with specific structural features, including various substituents and linkers, to enhance the inhibitory activity against tumor cells, improve targeting, and ensure stability and safety, as represented by structures such as formulae (II-A) to (III-C).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If camptothecin derivatives are used in ADCs for anti-tumor treatment, then anti-tumor effect is achieved by inhibiting topoisomerase I, but therapeutic efficacy and safety are insufficient
Solution Approach 1:
The patent modifies the chemical structure of camptothecin derivatives by changing parameters such as substituting hydroxyl groups with methoxy groups, introducing fluorine atoms, and modifying ring structures to create compounds with improved therapeutic index while maintaining topoisomerase I inhibition activity
Solution Approach 2:
The patent creates composite structures by combining camptothecin core structures with various substituent groups and linker moieties to form ADC conjugates that integrate targeting, delivery, and cytotoxic functions into a single therapeutic agent
2Reliability
If camptothecin derivatives are developed to enhance inhibitory activity against tumor cells, then anti-tumor effect is improved, but plasma stability may be compromised
Solution Approach 1:
The patent optimizes the balance between activity and stability by modifying chemical parameters such as replacing labile hydroxyl groups with more stable methoxy or fluorine-substituted variants, and adjusting linker chemistry to achieve appropriate plasma half-life while maintaining potent topoisomerase I inhibition
3Reliability
If camptothecin derivatives are designed with enhanced targeting capability, then tumor specificity is improved, but device complexity increases
Solution Approach 1:
The patent segments the ADC molecule into distinct functional modules including a targeting ligand portion, a linker portion, and a camptothecin cytotoxic portion, allowing independent optimization of each module while maintaining overall functionality
Solution Approach 2:
The patent introduces linker molecules as intermediaries that connect the targeting ligand to the camptothecin payload, enabling modular assembly and simplifying the design process while achieving enhanced tumor targeting through the ligand-component
Data Source
AI summary
The present application relates to an anti-tumor compound and a preparation method and use thereof, and in particular to a compound or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a preparation method and use thereof.